Side-by-side financials for BOLT and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BOLT | LLY |
|---|---|---|
| Market cap | - | $1.093 T |
| US-listed rank | - | #11 |
| Revenue (latest FY) | $7.70M | $65.18B |
| Net income (latest FY) | -$33.38M | $20.64B |
| Net margin | -433.7% | 31.7% |
| P/E (trailing FY) | - | 53.0 |
| SEC filings | 278 | 989 |
In their latest fiscal years, Bolt Biotherapeutics, Inc. reported $7.70M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Bolt Biotherapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.